<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03305705</url>
  </required_header>
  <id_info>
    <org_study_id>BASEC-Nr. PB_2017-00429</org_study_id>
    <secondary_id>KEK-ZH-Nr. 2014-0217</secondary_id>
    <nct_id>NCT03305705</nct_id>
  </id_info>
  <brief_title>Effect of Iron on Cerebral Dopamine Receptor Density in Non-anaemic Premenopausal Women With Low Ferritin and Fatigue</brief_title>
  <official_title>Double-Blind, Single-Center Interventional Trial To Evaluate The Effect Of Intravenous Iron Versus Placebo On Cerebral Dopamine Receptor Density In Non Anaemic Premenopausal Women With Low Ferritin Levels And Fatigue</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albina Nowak, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the effect of intravenous iron substitution in non-anaemic
      premenopausal women with iron deficiency on:

        -  Changes in the cerebral Dopamine (DA) receptor density after iron substitution, shown by
           brain PET

        -  Reduction of fatigue and other neuropsychological symptoms after iron supplementation
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 23, 2017</start_date>
  <completion_date type="Anticipated">August 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>The patients will be blinded with respect to the treatment sequence. The outcome assessor (PET scan evaluator) will be blinded with respect to the participant identity and the date of the PET scan.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Dopamine (DA) receptor density</measure>
    <time_frame>6 weeks</time_frame>
    <description>Changes in the cerebral Dopamine (DA) receptor density determined by brain PET with the 11C-Raclopride tracer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fatigue</measure>
    <time_frame>6 weeks</time_frame>
    <description>Reduction of fatigue after iron supplementation determined by Fatigue Assessment Scale (FAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue</measure>
    <time_frame>6 weeks</time_frame>
    <description>Reduction of fatigue after iron supplementation determined by &quot;Würzburger Erschöpfungs-Inventar bei Multipler Sklerose&quot; (WEIMuS, in German) questionaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological symptoms</measure>
    <time_frame>6 weeks</time_frame>
    <description>Reduction of neuropsychological symptoms after iron supplementation determined by neuropsychological assessment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Fatigue</condition>
  <condition>Iron-deficiency</condition>
  <arm_group>
    <arm_group_label>Treatment Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with 0.9% sodium chloride (placebo) at Visit 1 and with iron carboxymaltose in 6 weeks at Visit 2. The patients will be blinded with respect to the treatment sequence.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with 0.9% sodium chloride (placebo) at Visit 1 and with iron carboxymaltose in 6 weeks at Visit 2. The patients will be blinded with respect to the treatment sequence.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iron Carboxymaltose</intervention_name>
    <description>Single intravenous infusion within 20 min</description>
    <arm_group_label>Treatment Arm 1</arm_group_label>
    <arm_group_label>Treatment Arm 2</arm_group_label>
    <other_name>Ferinject®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium chloride 0.9%</intervention_name>
    <description>Single intravenous infusion of 250 ml within 20 min</description>
    <arm_group_label>Treatment Arm 1</arm_group_label>
    <arm_group_label>Treatment Arm 2</arm_group_label>
    <other_name>NaCl 0.9 % (serves as Placebo)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy female subjects, Age &gt; 18 years, premenopausal, regularly menstruating

          -  BMI 18-25 kg/m2

          -  Serum ferritin level &lt; 15 μg/ml, Hb &gt; 120 g/L

          -  Adequate contraception during the study period

          -  Fatigue determined as 2 or more points in the basic questionnaire for fatigue

          -  Informed consent

        Exclusion Criteria:

          -  Day-night shift work

          -  11 or more points in the BDI

          -  No psychiatric disease (as assessed by neuropsychiatric assessment)

          -  15 or more points in the ISI

          -  Known hypersensitivity to iron carboxymaltose, iron sucrose or iron sulfate

          -  Intake of iron preparations during the last 8 weeks before the start of the trial
             protocol

          -  Pregnancy or lactation

          -  Any cardiovascular or pulmonary disease

          -  Acute or chronic infection/inflammation or malignancy

          -  Other obvious physical or psychiatric causes for fatigue (known mental disorders, e.g.
             depression)

          -  Chronic intake of concurrent medication (especially antipsychotic drugs), except oral
             contraceptives. Sporadic intake of NSAID or paracetamol, e.g. in the case of a common
             cold or sporadic headaches is allowed.

          -  CRP &gt; 10 mg/L

          -  TSH out of normal range

          -  Any concurrent medical condition(s) that, in the view of the investigator, would
             prevent compliance or participation or jeopardize the health of the patients.

          -  Participation in any other therapeutic trial within the previous month

          -  Known History of HIV/HBV/HCV
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albina Nowak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Zurich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Albina Nowak, MD</last_name>
    <phone>+41 (0)44 255 10 54</phone>
    <email>albina.nowak@usz.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Zurich</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yulia Butscheid, PhD</last_name>
      <email>iron-dopamine@usz.ch</email>
    </contact>
    <investigator>
      <last_name>Yulia Butscheid, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2017</study_first_submitted>
  <study_first_submitted_qc>October 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 10, 2017</study_first_posted>
  <last_update_submitted>October 12, 2017</last_update_submitted>
  <last_update_submitted_qc>October 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Zurich</investigator_affiliation>
    <investigator_full_name>Albina Nowak, MD</investigator_full_name>
    <investigator_title>senior physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatigue</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
    <mesh_term>Dopamine</mesh_term>
    <mesh_term>Ferric Compounds</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

